VIDEO: Longer follow-up on pirtobrutinib shows increased response for mantle cell lymphoma
Click Here to Manage Email Alerts
In this video, Jakub Svoboda, MD, discusses an update on pirtobrutinib, which was recently approved for relapsing mantle cell lymphoma that has been previously treated with Bruton tyrosine kinase inhibitors.
The original BRUIN trial showed a high response rate to pirtobrutinib (Jaypirca, Eli Lilly & Co.), Svoboda, associate professor of medicine at Hospital of the University of Pennsylvania, said.
New data, presented at ASCO Annual Meeting examined overall response rates, complete response (CR) rates and duration of response after approximately 2 years.
"What's interesting is that the responses, especially the CR rates, seemed to have increased, which kind of suggests what we've seen with other BTK inhibitors — that there could be deepening of the remission with time," Svoboda said.
In addition, no new toxicity signals were found, Svoboda said.
Reference :
- Shah NN, et al. Abstract 7514. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Collapse
Read more about
Click Here to Manage Email Alerts